ADC Therapeutics SA
$4.25
▼
-0.53%
2026-04-21 05:04:01
www.adctherapeutics.com
NYQ: ADCT
Explore ADC Therapeutics SA stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$543.75 M
Current Price
$4.25
52W High / Low
$4.98 / $1.13
Stock P/E
—
Book Value
$-1.48
Dividend Yield
—
ROCE
-42.38%
ROE
73.43%
Face Value
—
EPS
$-1.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
188
Beta
1.95
Debt / Equity
-0.63
Current Ratio
4.37
Quick Ratio
4.31
Forward P/E
-2.51
Price / Sales
5.84
Enterprise Value
$653.36 M
EV / EBITDA
-6.2
EV / Revenue
8.03
Rating
Strong Buy
Target Price
$8.2
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Roivant Sciences Ltd. | $29.41 | — | $21.16 B | — | -21.06% | -19.14% | $30.33 / $10.01 | $6.02 |
| 2. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 3. | Harmony Biosciences Holdings, Inc. | $29.53 | 10.93 | $1.73 B | — | 20.45% | 20.75% | $40.87 / $25.52 | $15.07 |
| 4. | Neumora Therapeutics, Inc. | $2.19 | — | $391.39 M | — | -152.06% | -1.21% | $3.65 / $0.61 | $0.6 |
| 5. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 6. | Marker Therapeutics, Inc. | $1.67 | — | $27.84 M | — | -74.05% | -68.81% | $4.07 / $0.81 | $1.01 |
| 7. | Agios Pharmaceuticals, Inc. | $27.07 | — | $1.54 B | — | -38.86% | -30.2% | $46 / $22.24 | $20.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 23.06 M | 16.43 M | 18.84 M | 23.03 M | 16.91 M | — |
| Operating Profit | -18.12 M | -30.33 M | -30.57 M | -28.18 M | -32.21 M | — |
| Net Profit | -6.41 M | -40.97 M | -56.65 M | -38.6 M | -30.73 M | — |
| EPS in Rs | -0.05 | -0.32 | -0.45 | -0.3 | -0.24 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 81.36 M | 70.84 M | 69.56 M | 209.91 M |
| Operating Profit | -107.21 M | -129.59 M | -165.05 M | -122.99 M |
| Net Profit | -142.62 M | -157.85 M | -240.05 M | -157.13 M |
| EPS in Rs | -1.12 | -1.24 | -1.89 | -1.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 323.15 M | 321.98 M | 354.78 M | 490.86 M |
| Total Liabilities | 508.98 M | 524.62 M | 503.03 M | 411.41 M |
| Equity | -185.83 M | -202.64 M | -148.25 M | 79.45 M |
| Current Assets | 306.33 M | 291.25 M | 336.29 M | 434.98 M |
| Current Liabilities | 70.16 M | 80.47 M | 67.67 M | 81.94 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -141.17 M | -123.83 M | -118.69 M | -138.31 M |
| Investing CF | 0.4 M | -0.87 M | -3.22 M | -0.69 M |
| Financing CF | 150.94 M | 97.05 M | 73.88 M | -0.9 M |
| Free CF | -141.44 M | -124.7 M | -121.9 M | -139 M |
| Capex | -0.26 M | -0.87 M | -3.22 M | -0.69 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 1.84% | -66.86% | — | — |
| Earnings Growth % | 34.25% | -52.78% | — | — |
| Profit Margin % | -222.83% | -345.11% | -74.86% | — |
| Operating Margin % | -182.94% | -237.29% | -58.59% | — |
| Gross Margin % | 91.6% | 96.36% | 98.43% | — |
| EBITDA Margin % | -144.91% | -209.65% | -51.31% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.